Trial Profile

A Phase I, Open-Label, Multicentre, Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 8835 (Primary) ; Fulvestrant (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Solid tumours
Focus Adverse reactions
Sponsors AstraZeneca

Most Recent Events

07 Oct 2016 Status changed from active, no longer recruiting to completed.
28 Jun 2016 Status changed from recruiting to active, no longer recruiting.
12 Jan 2015 Planned End Date changed from 1 Nov 2017 to 1 May 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com